1.Age classification for tooth loss management in Korean adults
Jong-Im CHOI ; Hyun-Jeong JU ; Heung-Soo LEE ; Hyo-Won OH
Journal of Korean Academy of Oral Health 2025;49(1):48-54
Objectives:
To propose age group classification criteria for efficient tooth loss management by ana-lyzing the distribution of tooth loss in Korean adults by age group and causes of tooth loss. In addi-tion, to determine the efficacy of a Significant Tooth Loss index.
Methods:
The study included 13,199 adults who participated in the seventh Korea National Health and Nutrition Examination Survey (2016-2018). The mean number of missing teeth was compared by classifying the ages into 10- and 5-year intervals. Based on this analysis, the distribution of missing teeth was determined by classifying the age groups into 15-year intervals. Subsequently, the causes of tooth loss by age group at 15-year intervals and the efficacy of the Significant Tooth Loss Index were determined.
Results:
Classification at 5-year age intervals was more appropriate for analyzing changes in the distribution of missing teeth than classification at 10-year age intervals. However, establishing a public oral health program for the management of tooth loss on a 5-year or 10-year basis is im-practical. Therefore, a classification method with 15-year age intervals was proposed, in which the groups were young (19-34 years), middle-aged (35-49 years), older adult (50-64 years), and elderly (65 years or older). Although the criteria for the Significant Tooth Loss Index were appropri-ate for the young, older adults, and elderly groups, modifications were required for the middle-aged group.
Conclusions
Age-based oral health programs for adults should be promoted to prevent tooth loss by classifying adults into different age groups based on their clinical characteristics.
2.Age classification for tooth loss management in Korean adults
Jong-Im CHOI ; Hyun-Jeong JU ; Heung-Soo LEE ; Hyo-Won OH
Journal of Korean Academy of Oral Health 2025;49(1):48-54
Objectives:
To propose age group classification criteria for efficient tooth loss management by ana-lyzing the distribution of tooth loss in Korean adults by age group and causes of tooth loss. In addi-tion, to determine the efficacy of a Significant Tooth Loss index.
Methods:
The study included 13,199 adults who participated in the seventh Korea National Health and Nutrition Examination Survey (2016-2018). The mean number of missing teeth was compared by classifying the ages into 10- and 5-year intervals. Based on this analysis, the distribution of missing teeth was determined by classifying the age groups into 15-year intervals. Subsequently, the causes of tooth loss by age group at 15-year intervals and the efficacy of the Significant Tooth Loss Index were determined.
Results:
Classification at 5-year age intervals was more appropriate for analyzing changes in the distribution of missing teeth than classification at 10-year age intervals. However, establishing a public oral health program for the management of tooth loss on a 5-year or 10-year basis is im-practical. Therefore, a classification method with 15-year age intervals was proposed, in which the groups were young (19-34 years), middle-aged (35-49 years), older adult (50-64 years), and elderly (65 years or older). Although the criteria for the Significant Tooth Loss Index were appropri-ate for the young, older adults, and elderly groups, modifications were required for the middle-aged group.
Conclusions
Age-based oral health programs for adults should be promoted to prevent tooth loss by classifying adults into different age groups based on their clinical characteristics.
3.Age classification for tooth loss management in Korean adults
Jong-Im CHOI ; Hyun-Jeong JU ; Heung-Soo LEE ; Hyo-Won OH
Journal of Korean Academy of Oral Health 2025;49(1):48-54
Objectives:
To propose age group classification criteria for efficient tooth loss management by ana-lyzing the distribution of tooth loss in Korean adults by age group and causes of tooth loss. In addi-tion, to determine the efficacy of a Significant Tooth Loss index.
Methods:
The study included 13,199 adults who participated in the seventh Korea National Health and Nutrition Examination Survey (2016-2018). The mean number of missing teeth was compared by classifying the ages into 10- and 5-year intervals. Based on this analysis, the distribution of missing teeth was determined by classifying the age groups into 15-year intervals. Subsequently, the causes of tooth loss by age group at 15-year intervals and the efficacy of the Significant Tooth Loss Index were determined.
Results:
Classification at 5-year age intervals was more appropriate for analyzing changes in the distribution of missing teeth than classification at 10-year age intervals. However, establishing a public oral health program for the management of tooth loss on a 5-year or 10-year basis is im-practical. Therefore, a classification method with 15-year age intervals was proposed, in which the groups were young (19-34 years), middle-aged (35-49 years), older adult (50-64 years), and elderly (65 years or older). Although the criteria for the Significant Tooth Loss Index were appropri-ate for the young, older adults, and elderly groups, modifications were required for the middle-aged group.
Conclusions
Age-based oral health programs for adults should be promoted to prevent tooth loss by classifying adults into different age groups based on their clinical characteristics.
4.Age classification for tooth loss management in Korean adults
Jong-Im CHOI ; Hyun-Jeong JU ; Heung-Soo LEE ; Hyo-Won OH
Journal of Korean Academy of Oral Health 2025;49(1):48-54
Objectives:
To propose age group classification criteria for efficient tooth loss management by ana-lyzing the distribution of tooth loss in Korean adults by age group and causes of tooth loss. In addi-tion, to determine the efficacy of a Significant Tooth Loss index.
Methods:
The study included 13,199 adults who participated in the seventh Korea National Health and Nutrition Examination Survey (2016-2018). The mean number of missing teeth was compared by classifying the ages into 10- and 5-year intervals. Based on this analysis, the distribution of missing teeth was determined by classifying the age groups into 15-year intervals. Subsequently, the causes of tooth loss by age group at 15-year intervals and the efficacy of the Significant Tooth Loss Index were determined.
Results:
Classification at 5-year age intervals was more appropriate for analyzing changes in the distribution of missing teeth than classification at 10-year age intervals. However, establishing a public oral health program for the management of tooth loss on a 5-year or 10-year basis is im-practical. Therefore, a classification method with 15-year age intervals was proposed, in which the groups were young (19-34 years), middle-aged (35-49 years), older adult (50-64 years), and elderly (65 years or older). Although the criteria for the Significant Tooth Loss Index were appropri-ate for the young, older adults, and elderly groups, modifications were required for the middle-aged group.
Conclusions
Age-based oral health programs for adults should be promoted to prevent tooth loss by classifying adults into different age groups based on their clinical characteristics.
5.Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate-Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factors (ENSEMBLE)
Nam Hoon KIM ; Juneyoung LEE ; Suk CHON ; Jae Myung YU ; In-Kyung JEONG ; Soo LIM ; Won Jun KIM ; Keeho SONG ; Ho Chan CHO ; Hea Min YU ; Kyoung-Ah KIM ; Sang Soo KIM ; Soon Hee LEE ; Chong Hwa KIM ; Soo Heon KWAK ; Yong‐ho LEE ; Choon Hee CHUNG ; Sihoon LEE ; Heung Yong JIN ; Jae Hyuk LEE ; Gwanpyo KOH ; Sang-Yong KIM ; Jaetaek KIM ; Ju Hee LEE ; Tae Nyun KIM ; Hyun Jeong JEON ; Ji Hyun LEE ; Jae-Han JEON ; Hye Jin YOO ; Hee Kyung KIM ; Hyeong-Kyu PARK ; Il Seong NAM-GOONG ; Seongbin HONG ; Chul Woo AHN ; Ji Hee YU ; Jong Heon PARK ; Keun-Gyu PARK ; Chan Ho PARK ; Kyong Hye JOUNG ; Ohk-Hyun RYU ; Keun Yong PARK ; Eun-Gyoung HONG ; Bong-Soo CHA ; Kyu Chang WON ; Yoon-Sok CHUNG ; Sin Gon KIM
Endocrinology and Metabolism 2024;39(5):722-731
Background:
Atherogenic dyslipidemia, which is frequently associated with type 2 diabetes (T2D) and insulin resistance, contributes to the development of vascular complications. Statin therapy is the primary approach to dyslipidemia management in T2D, however, the role of non-statin therapy remains unclear. Ezetimibe reduces cholesterol burden by inhibiting intestinal cholesterol absorption. Fibrates lower triglyceride levels and increase high-density lipoprotein cholesterol (HDL-C) levels via peroxisome proliferator- activated receptor alpha agonism. Therefore, when combined, these drugs effectively lower non-HDL-C levels. Despite this, few clinical trials have specifically targeted non-HDL-C, and the efficacy of triple combination therapies, including statins, ezetimibe, and fibrates, has yet to be determined.
Methods:
This is a multicenter, prospective, randomized, open-label, active-comparator controlled trial involving 3,958 eligible participants with T2D, cardiovascular risk factors, and elevated non-HDL-C (≥100 mg/dL). Participants, already on moderate-intensity statins, will be randomly assigned to either Ezefeno (ezetimibe/fenofibrate) addition or statin dose-escalation. The primary end point is the development of a composite of major adverse cardiovascular and diabetic microvascular events over 48 months.
Conclusion
This trial aims to assess whether combining statins, ezetimibe, and fenofibrate is as effective as, or possibly superior to, statin monotherapy intensification in lowering cardiovascular and microvascular disease risk for patients with T2D. This could propose a novel therapeutic approach for managing dyslipidemia in T2D.
6.Clinical Trial Protocol for Porcine Islet Xenotransplantation in South Korea
Byung-Joon KIM ; Jun-Seop SHIN ; Byoung-Hoon MIN ; Jong-Min KIM ; Chung-Gyu PARK ; Hee-Jung KANG ; Eung Soo HWANG ; Won-Woo LEE ; Jung-Sik KIM ; Hyun Je KIM ; Iov KWON ; Jae Sung KIM ; Geun Soo KIM ; Joonho MOON ; Du Yeon SHIN ; Bumrae CHO ; Heung-Mo YANG ; Sung Joo KIM ; Kwang-Won KIM
Diabetes & Metabolism Journal 2024;48(6):1160-1168
Background:
Islet transplantation holds promise for treating selected type 1 diabetes mellitus patients, yet the scarcity of human donor organs impedes widespread adoption. Porcine islets, deemed a viable alternative, recently demonstrated successful longterm survival without zoonotic risks in a clinically relevant pig-to-non-human primate islet transplantation model. This success prompted the development of a clinical trial protocol for porcine islet xenotransplantation in humans.
Methods:
A single-center, open-label clinical trial initiated by the sponsor will assess the safety and efficacy of porcine islet transplantation for diabetes patients at Gachon Hospital. The protocol received approval from the Gachon Hospital Institutional Review Board (IRB) and the Korean Ministry of Food and Drug Safety (MFDS) under the Investigational New Drug (IND) process. Two diabetic patients, experiencing inadequate glycemic control despite intensive insulin treatment and frequent hypoglycemic unawareness, will be enrolled. Participants and their family members will engage in deliberation before xenotransplantation during the screening period. Each patient will receive islets isolated from designated pathogen-free pigs. Immunosuppressants and systemic infection prophylaxis will follow the program schedule. The primary endpoint is to confirm the safety of porcine islets in patients, and the secondary endpoint is to assess whether porcine islets can reduce insulin dose and the frequency of hypoglycemic unawareness.
Conclusion
A clinical trial protocol adhering to global consensus guidelines for porcine islet xenotransplantation is presented, facilitating streamlined implementation of comparable human trials worldwide.
7.Clinical Trial Protocol for Porcine Islet Xenotransplantation in South Korea
Byung-Joon KIM ; Jun-Seop SHIN ; Byoung-Hoon MIN ; Jong-Min KIM ; Chung-Gyu PARK ; Hee-Jung KANG ; Eung Soo HWANG ; Won-Woo LEE ; Jung-Sik KIM ; Hyun Je KIM ; Iov KWON ; Jae Sung KIM ; Geun Soo KIM ; Joonho MOON ; Du Yeon SHIN ; Bumrae CHO ; Heung-Mo YANG ; Sung Joo KIM ; Kwang-Won KIM
Diabetes & Metabolism Journal 2024;48(6):1160-1168
Background:
Islet transplantation holds promise for treating selected type 1 diabetes mellitus patients, yet the scarcity of human donor organs impedes widespread adoption. Porcine islets, deemed a viable alternative, recently demonstrated successful longterm survival without zoonotic risks in a clinically relevant pig-to-non-human primate islet transplantation model. This success prompted the development of a clinical trial protocol for porcine islet xenotransplantation in humans.
Methods:
A single-center, open-label clinical trial initiated by the sponsor will assess the safety and efficacy of porcine islet transplantation for diabetes patients at Gachon Hospital. The protocol received approval from the Gachon Hospital Institutional Review Board (IRB) and the Korean Ministry of Food and Drug Safety (MFDS) under the Investigational New Drug (IND) process. Two diabetic patients, experiencing inadequate glycemic control despite intensive insulin treatment and frequent hypoglycemic unawareness, will be enrolled. Participants and their family members will engage in deliberation before xenotransplantation during the screening period. Each patient will receive islets isolated from designated pathogen-free pigs. Immunosuppressants and systemic infection prophylaxis will follow the program schedule. The primary endpoint is to confirm the safety of porcine islets in patients, and the secondary endpoint is to assess whether porcine islets can reduce insulin dose and the frequency of hypoglycemic unawareness.
Conclusion
A clinical trial protocol adhering to global consensus guidelines for porcine islet xenotransplantation is presented, facilitating streamlined implementation of comparable human trials worldwide.
8.Clinical Trial Protocol for Porcine Islet Xenotransplantation in South Korea
Byung-Joon KIM ; Jun-Seop SHIN ; Byoung-Hoon MIN ; Jong-Min KIM ; Chung-Gyu PARK ; Hee-Jung KANG ; Eung Soo HWANG ; Won-Woo LEE ; Jung-Sik KIM ; Hyun Je KIM ; Iov KWON ; Jae Sung KIM ; Geun Soo KIM ; Joonho MOON ; Du Yeon SHIN ; Bumrae CHO ; Heung-Mo YANG ; Sung Joo KIM ; Kwang-Won KIM
Diabetes & Metabolism Journal 2024;48(6):1160-1168
Background:
Islet transplantation holds promise for treating selected type 1 diabetes mellitus patients, yet the scarcity of human donor organs impedes widespread adoption. Porcine islets, deemed a viable alternative, recently demonstrated successful longterm survival without zoonotic risks in a clinically relevant pig-to-non-human primate islet transplantation model. This success prompted the development of a clinical trial protocol for porcine islet xenotransplantation in humans.
Methods:
A single-center, open-label clinical trial initiated by the sponsor will assess the safety and efficacy of porcine islet transplantation for diabetes patients at Gachon Hospital. The protocol received approval from the Gachon Hospital Institutional Review Board (IRB) and the Korean Ministry of Food and Drug Safety (MFDS) under the Investigational New Drug (IND) process. Two diabetic patients, experiencing inadequate glycemic control despite intensive insulin treatment and frequent hypoglycemic unawareness, will be enrolled. Participants and their family members will engage in deliberation before xenotransplantation during the screening period. Each patient will receive islets isolated from designated pathogen-free pigs. Immunosuppressants and systemic infection prophylaxis will follow the program schedule. The primary endpoint is to confirm the safety of porcine islets in patients, and the secondary endpoint is to assess whether porcine islets can reduce insulin dose and the frequency of hypoglycemic unawareness.
Conclusion
A clinical trial protocol adhering to global consensus guidelines for porcine islet xenotransplantation is presented, facilitating streamlined implementation of comparable human trials worldwide.
9.Clinical Trial Protocol for Porcine Islet Xenotransplantation in South Korea
Byung-Joon KIM ; Jun-Seop SHIN ; Byoung-Hoon MIN ; Jong-Min KIM ; Chung-Gyu PARK ; Hee-Jung KANG ; Eung Soo HWANG ; Won-Woo LEE ; Jung-Sik KIM ; Hyun Je KIM ; Iov KWON ; Jae Sung KIM ; Geun Soo KIM ; Joonho MOON ; Du Yeon SHIN ; Bumrae CHO ; Heung-Mo YANG ; Sung Joo KIM ; Kwang-Won KIM
Diabetes & Metabolism Journal 2024;48(6):1160-1168
Background:
Islet transplantation holds promise for treating selected type 1 diabetes mellitus patients, yet the scarcity of human donor organs impedes widespread adoption. Porcine islets, deemed a viable alternative, recently demonstrated successful longterm survival without zoonotic risks in a clinically relevant pig-to-non-human primate islet transplantation model. This success prompted the development of a clinical trial protocol for porcine islet xenotransplantation in humans.
Methods:
A single-center, open-label clinical trial initiated by the sponsor will assess the safety and efficacy of porcine islet transplantation for diabetes patients at Gachon Hospital. The protocol received approval from the Gachon Hospital Institutional Review Board (IRB) and the Korean Ministry of Food and Drug Safety (MFDS) under the Investigational New Drug (IND) process. Two diabetic patients, experiencing inadequate glycemic control despite intensive insulin treatment and frequent hypoglycemic unawareness, will be enrolled. Participants and their family members will engage in deliberation before xenotransplantation during the screening period. Each patient will receive islets isolated from designated pathogen-free pigs. Immunosuppressants and systemic infection prophylaxis will follow the program schedule. The primary endpoint is to confirm the safety of porcine islets in patients, and the secondary endpoint is to assess whether porcine islets can reduce insulin dose and the frequency of hypoglycemic unawareness.
Conclusion
A clinical trial protocol adhering to global consensus guidelines for porcine islet xenotransplantation is presented, facilitating streamlined implementation of comparable human trials worldwide.
10.Resective Epilepsy Surgery after Corpus Callosotomy in Children with Lennox-Gastaut Syndrome
Soyoung PARK ; Hye Eun KWON ; Chung Mo KOO ; Yun Jung HUR ; Hoon-Chul KANG ; Joon Soo LEE ; Heung Dong KIM
Annals of Child Neurology 2024;32(1):13-20
Purpose:
This study examined the characteristics and outcomes of resective epilepsy surgery following corpus callosotomy (CC) in children with Lennox-Gastaut syndrome (LGS).
Methods:
We retrospectively analyzed 17 children with LGS who underwent resective surgery (RS) after CC over a span of 10 years, with a minimum of 2 years of follow-up, at a single tertiary epilepsy center in Korea.
Results:
Of the 17 patients, 13 (73.5%) demonstrated favorable surgical outcomes (Engel class I or II) at 1 year after RS, and eight (47.1%) were ultimately free of seizures 2 years after surgery. A significantly larger decrease in the number of anti-seizure medications taken from before to 2 years after the final surgical procedure was observed in the group that became seizure-free than in the group with persistent seizures (P=0.062). Furthermore, a significantly greater decline in daily adaptive function was found in the persistent seizure group (P=0.059). The baseline characteristics, results of presurgical evaluation, and treatment-related factors assessed prior to surgery showed no significant differences between the seizure-free group and the group with persistent seizures.
Conclusion
In conclusion, RS may be a viable option for patients with LGS who exhibit lateralization and/or localization on presurgical evaluation after CC, as the procedure may reveal a concealed primary focus. The proactive implementation of two-stage epilepsy surgery could provide significant seizure reduction and preservation of cognitive function in carefully selected patients with LGS.

Result Analysis
Print
Save
E-mail